American Gene Technologies

Jeff Galvin, CEO
Rockville, MD
American Gene Technologies (AGT) is a clinical-stage gene and cell therapy company with a gene-delivery platform for the rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. It expects to take its patented lead candidate for an HIV cure into the clinic in 2020. AGT has received eight patents for its immuno-oncology approach to stimulate gamma-delta (γδ) T-cells to destroy a variety of solid tumors. It has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. This treatment was granted an FDA Orphan Drug Designation and it is expected to reach the clinic in 2022.

By using this website you agree to accept our Privacy Policy and Terms & Conditions